Remedy hires Epstein as special adviser to Board of Directors

Remedy Pharmaceuticals has named David Epstein a special adviser to the Board of Directors.
"We are honored to be working with David,” Remedy Pharmaceuticals Executive Chairman David Geliebter said. “His unparalleled experience in drug development and commercialization will be indispensable as we continue to advance our product pipeline and explore prospective strategic alliances.”
Prior to Remedy, Epstein spend 25 years with Novartis. His most recent position with Novartis was Division Head and CEO of the Pharmaceuticals business. Epstein also founded and was head of the Oncology and Molecular Diagnostics units during his time with Novartis. The Oncology business rose to No. 2 in the world under his leadership. He brings with him more than two decades of experience in extensive drug development, deal making, commercialization and leadership on a worldwide scale. Epstein was the lead for the development and commercialization of 30 new molecular entities.
"I am excited about the science and the progress made to date," Epstein said. “My goal is to help Remedy’s executive team accelerate their program so that as many patients as possible can benefit from this lifesaving medicine."